Shi, G., Huang, X., Wen, T., Song, T., Kuang, M., Mou, H., . . . Zhou, J. (2023). Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements. Cancer Medicine, 12(4), 4137. https://doi.org/10.1002/cam4.5273
Chicago-referens (17:e uppl.)Shi, Guo‐Ming, et al. "Pemigatinib in Previously Treated Chinese Patients with Locally Advanced or Metastatic Cholangiocarcinoma Carrying FGFR2 Fusions or Rearrangements." Cancer Medicine 12, no. 4 (2023): 4137. https://doi.org/10.1002/cam4.5273.
MLA-referens (9:e uppl.)Shi, Guo‐Ming, et al. "Pemigatinib in Previously Treated Chinese Patients with Locally Advanced or Metastatic Cholangiocarcinoma Carrying FGFR2 Fusions or Rearrangements." Cancer Medicine, vol. 12, no. 4, 2023, p. 4137, https://doi.org/10.1002/cam4.5273.
